Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Of The Analgesic Efficacy And Safety Of Subcutaneous Administration Of Tanezumab In Patients With Osteoarthritis Of The Knee.

Trial Profile

Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Of The Analgesic Efficacy And Safety Of Subcutaneous Administration Of Tanezumab In Patients With Osteoarthritis Of The Knee.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 02 Nov 2012

At a glance

  • Drugs Tanezumab (Primary) ; Tanezumab (Primary)
  • Indications Musculoskeletal pain; Osteoarthritis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Most Recent Events

    • 01 May 2012 Actual patient number is 1 according to ClinicalTrials.gov record (Extension trial; NCT01127893).
    • 01 May 2012 Actual patient number is 1 according to ClinicalTrials.gov record (Extension trial; NCT01127893).
    • 01 May 2012 Actual initiation date (Jun 2010) added as reported by ClinicalTrials.gov (Extension trial; NCT01127893).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top